Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats

Biological Psychiatry
Peter TurroneJose Nobrega


Continuous, but not intermittent, infusion with a conventional antipsychotic (haloperidol, HAL) can induce the vacuous chewing movement (VCM) syndrome in rats. The objective of this study was to determine whether continuous, versus intermittent, olanzapine (OLZ) infusion differently affects the development of VCMs. Experiment 1: Animals were treated with 7.5 mg/kg/day of OLZ or vehicle (VEH) via either minipump (MP) or daily subcutaneous (SC) injections for 8 weeks. Experiment 2: A separate group of rats were treated with 15 mg/kg/day of OLZ, or 1 mg/kg/day of HAL or VEH via MP for 8 weeks. Dopamine D2 receptor occupancy levels were measured, ex vivo, with [3H]-raclopride. Experiment 1: Rats receiving 7.5 mg/kg/day of OLZ via MP (51% D2 occupancy), but not those receiving the same dose via daily SC injections (94% peak D2 occupancy), showed significant VCM levels compared with control animals (p = .02). Experiment 2: Both OLZ (67% D2 occupancy) and HAL (79% D2 occupancy) led to similar increases in VCMs compared with VEH (p = .005). This study provides strong evidence that even an atypical antipsychotic like OLZ, which rarely gives rise to tardive dyskinesia in the clinic, can lead to the VCM syndrome in rats if the antipsychot...Continue Reading


Sep 1, 1990·The American Journal of Psychiatry·R YassaG Schwartz
Nov 13, 1990·European Journal of Pharmacology·B GlenthøjT G Bolwig
May 19, 1989·European Journal of Pharmacology·B Glenthøj, R Hemmingsen
Mar 1, 1982·The American Journal of Psychiatry·A M RosenC Cardenas
Dec 1, 1984·Hospital & Community Psychiatry·M B Goldman, D J Luchins
May 1, 1993·Psychological Medicine·P O'HaraJ Wing
Jul 1, 1996·Physiology & Behavior·R E SteinpreisA Harrington
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJ M Kane
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H Y Meltzer
Jan 5, 2002·CNS Drugs·Daniel TarsyFrank I Tarazi
Mar 29, 2002·Molecular Psychiatry·Johannes TauscherShitij Kapur
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Shitij KapurJose Nobrega
Jul 3, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Peter TurroneJose Nobrega


Jul 24, 2010·Schizophrenia Bulletin·Gary Remington, Shitij Kapur
Feb 7, 2007·Current Opinion in Psychiatry·Gary Remington
Mar 13, 2012·Behavioral and Brain Functions : BBF·Pierre J BlanchetDaniel Lévesque
Aug 1, 2013·Journal of Clinical Psychopharmacology·Sho MoriguchiHiroyuki Uchida
Dec 23, 2008·Neurotoxicology·Marloes J A JoosenHerman P M van Helden
Feb 26, 2008·Biological Psychiatry·Anne-Noël SamahaShitij Kapur
Dec 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rossella MedoriGerhard Gründer
Jan 11, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yuya MizunoHiroyuki Uchida
Aug 16, 2011·Pharmacology, Biochemistry, and Behavior·Gary RemingtonSridhar Natesan
Jun 26, 2010·Current Protocols in Neuroscience·Roberto Coccurello, Anna Moles
Jul 29, 2017·Expert Review of Neurotherapeutics·Haitham SalemAntonio L Teixeira
Dec 22, 2020·Behavioural Brain Research·Alice ServonnetAnne-Noël Samaha
Jan 31, 2021·Behavioural Brain Research·Daria A ChestnykhChristian P Müller

Related Concepts

Behavior, Animal
Dyskinesia, Medication-Induced
Intravenous Drug Delivery Systems
Radioligand Assay

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here